Document Detail


Safety and effectiveness of indomethacin versus ibuprofen for treatment of patent ductus arteriosus.
MedLine Citation:
PMID:  20013605     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We compared the rates of medical closure of patent ductus arteriosus (PDA) and complications (renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and intraventricular hemorrhage) between infants treated with indomethacin and infants treated with ibuprofen. We performed a retrospective comparative cohort study of infants treated with indomethacin or ibuprofen for symptomatic PDA at Duke University Medical Center between November 2005 and November 2007. We identified 65 infants who received indomethacin and 57 who received ibuprofen. The rate of survival without surgical ductal ligation was 62% (40/65) in the indomethacin group and 58% (33/57) in the ibuprofen group (p = 0.71). The rate of the composite of complications (death, necrotizing enterocolitis, or intestinal perforation) was 40% (26/65) in the indomethacin group and 32% (18/57) in the ibuprofen group (p = 0.35). There was no significant difference between groups in elevation of serum creatinine during treatment. In clinical practice, ibuprofen appears to be as effective as indomethacin for closure of patent ductus arteriosus with similar complication rates. The decision to use one agent over the other should be based on dose schedule preference and the currently published clinical trials until more safety and effectiveness data are available.
Authors:
Lakshmi I Katakam; C Michael Cotten; Ronald N Goldberg; Chi N Dang; P Brian Smith
Related Documents :
1256945 - Incidence and clinical features of patent ductus arteriosus in low-birthweight infants:...
15882935 - Diagnosis and treatment of neonatal hypotension outside the transitional period.
8201485 - Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicent...
2360535 - The timing of spontaneous closure of the ductus arteriosus in infants with respiratory ...
23143545 - Reduced neonatal lung function and wheezing illnesses during the first 5 years of life.
8471415 - The n-demethylation of imipramine correlates with the oxidation of s-mephenytoin (s/r-r...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-12-11
Journal Detail:
Title:  American journal of perinatology     Volume:  27     ISSN:  1098-8785     ISO Abbreviation:  Am J Perinatol     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-26     Completed Date:  2010-09-21     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  8405212     Medline TA:  Am J Perinatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  425-9     Citation Subset:  IM    
Copyright Information:
Copyright Thieme Medical Publishers.
Affiliation:
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ductus Arteriosus, Patent / drug therapy*
Female
Humans
Ibuprofen / pharmacology,  therapeutic use*
Indomethacin / pharmacology,  therapeutic use*
Infant, Newborn
Male
Retrospective Studies
Treatment Outcome
Grant Support
ID/Acronym/Agency:
1K23HD060040-01/HD/NICHD NIH HHS; 1U10H040492-01//PHS HHS; K23 HD060040-01/HD/NICHD NIH HHS; U10 HD040492/HD/NICHD NIH HHS; U10 HD040492-01/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
15687-27-1/Ibuprofen; 53-86-1/Indomethacin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Influence of Phototherapy on Serum Cytokine Concentrations in Newborn Infants.
Next Document:  N-terminal pro-B-type Natriuretic Peptide as a Marker of Bronchopulmonary Dysplasia in Premature Inf...